FIGURE 2.

A four protein‐based plasma EV‐score at treatment baseline robustly predicted immunotherapeutic outcomes. The prognostic correlations of EV‐derived (a) ARG1, (b) CD3, (c) PD‐L1 and (d) PD‐L2 at BL were assessed by Kaplan‐Meier survival analysis. These four genes were further combined to generated an EV‐score. (e) ROC curve was used to measure the specificity and sensitivity of EV‐derived ARG1, CD3, PD‐L1, PD‐L2 and EV‐score in characterizing patients reached an irPFS (progression) or irOS (survival) longer than 6 months. (f) Prognostic indications of scattered EV‐scores (left panel), or for the cut‐off value of EV‐score≥1 (right panel). (g) Timeline‐scaled changes of tumour volume and (h) the best changes of tumour volume for all patients were stratified by EV‐score. CT images and changes of tumour volume were displayed for representative cases defined as (i) EV‐score≥1 or (j) EV‐score < 1. (k) Correlation between EV‐score and IFN‐γ content in paired peripheral blood samples at BL